MFJ Stock Overview
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$1.15 |
52 Week High | AU$1.48 |
52 Week Low | AU$0.65 |
Beta | 1.6 |
1 Month Change | -8.00% |
3 Month Change | 4.55% |
1 Year Change | 12.75% |
3 Year Change | -40.10% |
5 Year Change | 86.39% |
Change since IPO | 106.46% |
Recent News & Updates
Recent updates
Shareholder Returns
MFJ | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -10.2% | -5.0% | -2.0% |
1Y | 12.7% | -13.6% | -0.3% |
Return vs Industry: MFJ exceeded the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: MFJ exceeded the German Market which returned -0.3% over the past year.
Price Volatility
MFJ volatility | |
---|---|
MFJ Average Weekly Movement | 7.1% |
Medical Equipment Industry Average Movement | 4.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MFJ's share price has been volatile over the past 3 months.
Volatility Over Time: MFJ's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 237 | Swami Raote | www.polynovo.com |
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.
PolyNovo Limited Fundamentals Summary
MFJ fundamental statistics | |
---|---|
Market cap | €825.40m |
Earnings (TTM) | €965.42k |
Revenue (TTM) | €50.54m |
855.0x
P/E Ratio16.3x
P/S RatioIs MFJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MFJ income statement (TTM) | |
---|---|
Revenue | AU$83.47m |
Cost of Revenue | AU$14.09m |
Gross Profit | AU$69.38m |
Other Expenses | AU$67.78m |
Earnings | AU$1.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.0023 |
Gross Margin | 83.12% |
Net Profit Margin | 1.91% |
Debt/Equity Ratio | 3.4% |
How did MFJ perform over the long term?
See historical performance and comparison